KTTA 8-K: Fda approval
Pasithea Therapeutics
Filed with the SEC on · accession 0001213900-26-120147
KTTA filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Pasithea Therapeutics announced initial positive clinical data from its Phase 1/1b study of PAS-004 in NF1-associated neurofibromas and received FDA clearance of its IND application for a Phase 2 trial in adults with NF1-associated cutaneous neurofibromas.
Key details
✦ Ask GOAX AI about this filing — what it means for KTTA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KTTA?
Click hereFrequently asked questions
What did KTTA file with the SEC on Nov 16, 2026?
KTTA filed a 8-K (Fda approval). Pasithea Therapeutics announced initial positive clinical data from its Phase 1/1b study of PAS-004 in NF1-associated neurofibromas and received FDA clearance of its IND application for a Phase 2 trial in adults with NF1-associated cutaneous neurofibromas.
What does a fda approval mean for KTTA stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other KTTA SEC filings
Get alerts when KTTA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days